CD79B

CD79B

CD79B Informations sur la molécule

Molecule Name
B-cell antigen receptor complex-associated protein beta chain
Alias de la molécule
CD79b,B29,IGB,Ig-beta
Drug Development Progress
Nombre de médicaments cliniques9
Nombre de médicaments commercialisés1
Phase de R&D la plus avancéeApproved
Alias de la cible
B-Cell Antigen Receptor Complex-Associated Protein Beta Chain,B29,Immunoglobulin-associated B29 protein,Ig-beta,B-cell-specific glycoprotein B29,CD79B,CD79b Molecule,CD79b Molecule, Immunoglobulin-Associated Beta,IGB,CD79B Antigen (Immunoglobulin-Associated Beta),CD79b Antigen,AGM6
Contexte de la molécule
B-cell antigen receptor complex-associated protein beta chain (CD79b) is also known as B-cell-specific glycoprotein B29, Ig-beta,Immunoglobulin-associated B29 protein, B29 and IGB, which is a single-pass type I membrane protein containing one Ig-like V-type ( immunoglobulin-like ) domain and one ITAM domain.CD79b is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR).CD79b can enhance phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Defects in CD79b are the cause of agammaglobulinemia type 6 (AGM6) that is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development.

CD79B Liste de produits

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
SHR-A1912SHR-A1912Phase 3 ClinicalShanghai Hengrui Pharmaceutical Co Ltd
Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse
Details
CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute)bi-4SCAR CD19/79bPhase 2 ClinicalShenzhen Geno-Immune Medical Institute
Leukemia, B-Cell; Lymphoma, B-Cell
Details
TolDCB29Phase 2 ClinicalUmc Utrecht
Arthritis, Rheumatoid
Details
JNJ-95566692JNJ-95566692Phase 1 ClinicalJanssen Research & Development Llc
Lymphoma, Non-Hodgkin
Details
LTZ-301LTZ-301Phase 1 ClinicalLTZ Therapeutics Inc
Autoimmune Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin
Details
CD79b-19 CAR T Cells Therapy (Massachusetts General Hospital)Phase 1 ClinicalMassachusetts General Hospital
Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Primary mediastinal B cell lymphoma
Details
Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy(MD Anderson Cancer Center)JV-213Phase 1 ClinicalThe University Of Texas MD Anderson Cancer Center
Lymphoma; Lymphoma, B-Cell
Details
NBT-508Phase 1 ClinicalNewbio Therapeutics Inc
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin
Details
CD79b CAR-T cell therapy (Yake Biotechnology)Phase 1 ClinicalShanghai YaKe Biotechnology Co Ltd, Zhejiang University
Leukemia, Biphenotypic, Acute; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
Polatuzumab vedotinRO-5541077-000; FCU-2711; DCDS-4501A; RG-7596; RO-5541077ApprovedGenentech Inc, Seagen IncPolivy, 优罗华United StatesLymphoma, Large B-Cell, DiffuseGenentech Inc2019-06-10
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin
Details